3Morrison LK, Harrison A, Krishnaswamy P. et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea[J]. J An Coll Cardiol, 2002,39(2) :202-209.
1Bozkurt B,Mann DL. Use of biomarkers in the management of heart failure. Are we there yet? Circulation ,2003,107 : 1231-1233.
2White HD,French JK. Use of brain natriuretic peptide levels for risk assessment in non-ST-elevation acute coronary syndromes. J Am Coll Cardiol,2003,42 : 1917-1920.
3Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure. European Society of Cardiology. Euro Heart J,2001,22 : 1527-1560.
4Hunt SA,Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. Circulation ,2005,112 :e154-e235.
6Yeo KTJ, Wu AHB, Apple FS, et al. Muhicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta,2003,338 : 107-115.
7Vasan RS. Expanding indications for natriuretic peptides:impottance of better new (research) protocols. Am Heart J ,2004,148:743-746.
8Panteghini M,Pagani F,Yeo KTJ,et al. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem,2004,50:327-332.
9Jaffe AS, Katus H. Acute coronary syndrome biomarkers: the need for more adequate reporting. Circulation ,2004,110 : 104-106.
10Redfield MM, Rodeheffer R J, Jacobsen SJ, et al. Plasma brain natriuretic peptide concentration : impact of age and gender. J Am Coll Cardiol,2002 ,40 :976-982.
